Navigation Links
AMIA Announces 2008 Summit on Translational Bioinformatics

ll focus on the topic of translational bioinformatics, is a clear indicator of the Association's strong commitment to serve as the professional home for practitioners in this domain and as a premier venue for reporting advances in the state of translational research."

The summit will take place March 12-15, 2008 at the Hilton San Francisco in San Francisco, California. A call for participation and program will be announced in the near future. For more information about AMIA's translational bioinformatics activities, visit the AMIA web site at: http://www.amia.org.

    Contact:  Tia Abner

              301-657-1291 ext. 105

              

tia@amia.org

About AMIA

The American Medical Informatics Association (AMIA) is a professional organization of leaders shaping the future of biomedical and health informatics in the United States and over 50 other nations. AMIA is dedicated to the development and application of informatics in support of patient care, public health, teaching, research, administration, and related policy. Complete information about AMIA is available at: http://www.amia.org.

CONTACT: Tia Abner of American Medical Informatics Association,+1-301-657-1291 ext. 105, tia@amia.org

Web site: http://www.amia.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AMIA Announces Summit Translational Bioinformatics
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... BEIJING, June 14, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... Mr. Xiaodong Wu, Chairman and Chief Executive Officer of ... of the Company,s American Depositary Shares ("ADSs") in the ...
... June 13, 2011 Tengion, Inc. (Nasdaq: ... trial of the Company,s lead clinical product candidate, the ... a urinary diversion following bladder removal (cystectomy). Tengion is ... approach as part of its ongoing clinical trial of ...
Cached Medicine Technology:China Medical Technologies Announces the Purchase of its ADSs by Chengxuan in the Open Market 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 3Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 4
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
(Date:4/23/2014)... 24, 2014 Pregnant immigrants from Sub-Saharan Africa, ... monitoring during pregnancy, according to new research from ... in the British Journal of Obstetrics and ... eclampsia rates among immigrants and native-born women in ... Denmark, Sweden, Spain (Catalonia and Valencia) and the ...
(Date:4/23/2014)... John J. O,Shea, M.D., scientific director at the National ... has been named the 2014 recipient of the Ross ... peer-reviewed, open-access journal Molecular Medicine . The award ... York Academy of Sciences in Manhattan, followed by scientific ... is part of the National Institutes of Health. , ...
(Date:4/23/2014)... that rats exposed to high-energy particles, simulating conditions astronauts ... lapses in attention and slower reaction times, even when ... , The cognitive impairments which affected a large ... appear to be linked to protein changes in the ... hold true in humans, suggest it may be possible ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... the age of forty with breast cancer who are given ... chemotherapy, may not be benefiting from these drugs. This is ... hormones such as estrogen, according to research published in the ... a young age is very worrying in terms of survival," ...
... Benefit, MARYSVILLE, Calif., Oct. 10 Yuba County ... filing of a,formal grievance over the county,s refusal to ... year. Because of the county,s unwillingness to abide ... elderly or have disabilities must play,a waiting game with ...
... Pa., Oct. 10 The following is,being issued by the Pennsylvania Breast Cancer Coalition:, WHAT: ... of the Pennsylvania Breast ... two-day event, held every October, is the premiere breast ... thousand attendees participate ...
... key protein that controls how stem cells choose to ... smooth muscle cells that support blood vessels, according to ... National Academy of Sciences (PNAS). The results not ... in the human fetus, but also suggest new ways ...
... (pronounced,zy-ince), one of the fastest growing brands in the ... has received access,to up to $12 million in a ... intends to use a significant portion of the,investment to ... Xenergy is a combination of Zen and Energy and ...
... say , WEDNESDAY, Oct. 10 (HealthDay News) -- Adult stem ... stem cells in an undifferentiated state, U.S. researchers report. , ... change into any kind of cell is regulated differently in ... also challenges findings from more than 50 studies that concluded ...
Cached Medicine News:Health News:Cancer conflict with chemotherapy treatment 2Health News:Caregivers Demand County Honor Their Contract 2Health News:PA Breast Cancer Coalition Announces Special Press Availability for PA Breast Cancer Coalition Annual Conference 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 3Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 4Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 5Health News:XYIENCE(R) Announces $12 Million Funding and Signing of Long Term UFC(R) Sponsorship 2Health News:Study Probes Difference Between Embryonic, Adult Stem Cells 2
... Single Use linear stapler with ... Auto Suture™ PREMIUM POLY CS™-57 disposable ... creation of a temporary opening, such ... cesarean section, or when transecting muscle ...
... Use reloadable linear stapler ... (DST™) titanium staples., ... Reloadable staplers has application ... and thoracic surgical procedures ...
... reloadable linear stapler for resection, transection and ... Suture™ MULTIFIRE GIA™ 60 and 80 single ... and 80 single use loading units and ... single use surgical stapler with MULTIFIRE SGIA™ ...
... With Titanium Staples for use with PI™ ... ,The PI™ disposable stapler is designed ... of normal, healthy internal tissues. The instrument ... staggered row, when using the 30 VASCULAR ...
Medicine Products: